**Core Concept:** Integrase inhibitors are a class of antiretroviral medications used in the treatment of HIV infection. They work by inhibiting the enzyme integrase, which is essential for HIV to integrate its genetic material into the host cell's genome. This prevents the production of new viral particles and helps to suppress viral replication.

**Why the Correct Answer is Right:** The correct answer, Dolutegravir (DTG), is a second-generation integrase strand transesterase inhibitor (INSTI) approved for the treatment of HIV. DTG works by binding to and inhibiting the integrase enzyme, which is required for HIV to integrate its genetic material into the host cell's genome. This prevents the production of new viral particles, leading to decreased viral replication and improved clinical outcomes.

**Why Each Wrong Option is Incorrect:**

A. Raltegravir (RAL) is also an INSTI, but it is a first-generation drug that was introduced before DTG. It has some limitations, including lower genetic barrier to resistance and lower potency compared to DTG.

B. Elvitegravir (EVG) is another INSTI, but it is also a first-generation drug. It has similar limitations as RAL, making it less effective and less suitable for modern HIV treatment regimens.

C. Ritonavir is a booster drug used to increase the plasma concentration of protease inhibitors (PIs) like Atripla (combination therapy). It does not belong to the integrase inhibitor class and is not used for the treatment of HIV infection.

**Clinical Pearl:** Integrase inhibitors are a crucial component of modern HIV treatment regimens due to their higher potency, genetic barrier to resistance, and improved pharmacokinetic properties. Dolutegravir is the most widely used INSTI in clinical practice, thanks to its superior pharmacokinetic properties and effectiveness.